Short-Term Debt to Equity Ratio: Avenue Therapeutics (ATXI)
The prospects for Avenue Therapeutics (ATXI) depend on regulatory verdicts regarding new analgesics and legal safety aspects. This daily price action, visualized for analytical convenience, reflects a metric of 0.00. Such high volatility is driven by the venture nature of the development portfolio. Meanwhile, the business focuses on creating non-opioid treatments for acute pain, which remains critical amid the global opioid crisis.
Analytical breakdowns for Avenue Therapeutics
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Avenue Therapeutics|ATXI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Avenue Therapeutics, Inc.|ATXI - Company Debts|Debts to Book Capitalization Avenue Therapeutics Inc.|ATXI - Long-Term Debt|Company Short-Term Debt Avenue Therapeutics|Quick Liquidity Indicator avenuetx.com
- company profitability and valuation multiples indicators:
General company analysis:Avenue Therapeutics, Inc
Professional managers filter assets by analyzing debt loads, utilizing the ratio of short-term liabilities (over one year) to equity to assess financial stability and liquidity risks. For Avenue Therapeutics (ATXI), whose model relies on costly outsourcing of compound synthesis via CMOs, this chart of short-term loan share relative to equity is critical for monitoring the company's ability to service vendor contracts.
Competitors of Avenue Therapeutics (ATXI)
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Capital denalitherapeutics.com|Short-Term Debt to Equity Ratio HRMY (Harmony Biosciences Holdings, Inc.)|Short-Term Debt to Equity BHVN (Biohaven Ltd)|Short-Term Debt to Capital AMLX (Amylyx)|Trevi Corp (TRVI) - Current Liabilities to Capital|PRAX - Short-Term Debt to Equity|AVXL (anavex.com) - Short-Term Debt to Capital Ratio|CBLL (CeriBell) - Short-Term Debt to Equity Ratio|Prothena Biosciences (PRTA) - Short-Term Debt to Capital|ALEC (Alector Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Annexon Biosciences Inc. ANNX|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|AC Immune SA - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio VYGR (Voyager Therapeutics Inc)|Neumora Therapeutics Inc - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN: Short-Term Debt to Capital|Current Liabilities to Capital Alpha Cognition Inc. (ACOG)|Short-Term Debt to Equity Cognition Therapeutics, Inc.|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SAVA|Short-Term Debt to Capital assertiotx.com (ASRT)|Short-Term Debt to Equity Coya Therapeutics COYA|VTGN (VistaGen Therapeutics, Inc.) - Current Liabilities to Equity|Ovid Rx - Short-Term Debt to Capital|Current Liabilities to Capital Acumen Pharmaceuticals Inc.|CRVO (CervoMed Inc) - Short-Term Debt to Equity Ratio|Alterity Therapeutics Limited (ATHE) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio CLNN|PEPG (PepGen Corp) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital JUNS|Short-Term Debt to Capital Coefficient Relmada Therapeutics Inc|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|GRCE - Short-Term Debt to Equity Ratio|AIFF - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Klotho Neurosciences Inc KLTO|NRSN: Short-Term Debt to Capital|Reviva Pharmaceuticals Holdings Inc. (RVPH) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio MTVA|NRXS (NeurAxis Inc) - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio HSDT (Helius Medical)|passagebio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital NEUP (Neuphoria Therapeutics)|Short-Term Debt to Capital Coefficient Minerva Neurosciences Inc (NERV)|ATHA - Short-Term Debt to Equity|ADXN (Addex) - Short-Term Debt to Capital Ratio|ALZN: Short-Term Debt to Capital|Current Liabilities to Capital Cyclerion Therapeutics, Inc. (CYCN)|Short-Term Debt to Equity Ratio PTIX|Short-Term Debt to Capital Pasithea|Short-Term Debt to Equity Cortigent, Inc. (CRGT)|BCLI (BrainStorm Cell Therapeutics Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|chromocell.com (CHRO) - Current Liabilities to Capital|Eliem - Short-Term Debt to Capital|ITCI - Short-Term Debt to Capital|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|MRNS (Marinus Pharma) - Short-Term Debt to Equity|NKGN (NKGen Biotech, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Sage Therapeutics (SAGE)|Synaptogenix Inc. - Short-Term Debt to Capital Ratio|Trevena, Inc - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Vigil Neuroscience Inc. VIGL|Anew Medical, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital cerevel.com